58:04

Advanced in vitro modelling of neuromuscular diseases and therapeutics

59:46

New Findings on Inequities in Rare Diseases: How They Impact Research and Clinical Trials Processes

01:01:29

CGIC Day 3: Regulatory Call to Action and Final Remarks

56:13

CGIC2024 Day 2: Applying Learnings to New Frontiers

01:05:11

CGIC2024 Day 2: Refining the Use of Data to Manage Uncertainty

13:30

CIVM Qualification Framework Workshop Day 2 Keynote Address Ksenia Blinova

11:17

Day 1 CIVM Qualification Framework Session 3 Context of Use part 3

14:54

Day 2 CIVM Qualification Framework Workshop, Keynote Address: David Strauss

01:21

CIVM Qualification Framework Workshop Day 2 Opening Remarks

32:04

CIVM Day 2 Breakout Session Recap

42:25

Day 1 CIVM Qualification Framework Workshop Session 3 Context of Use Panel

15:50

Day 1 CIVM Qualification Framework Workshop Session 3 Context of Use part 5

11:20

Day 1 CIVM Qualification Workshop Session 3 Context of Use part 4

11:41

Day 1CIVM Workshop Session 3 Context of Use part 2

07:13

Day 1 CIVM Workshop Session 3: Context of Use Part 1

41:38

CIVM Workshop Day 1 Panel 2 Broad Takeaways and How can we use Those Learnings

18:27

CIVM Qualification Workshop Session 2: Applying Specific Examples to Broader Applications part 1

31:02

CIVM Qualification Framework Workshop Session 1: Global Perspective and Discussion of Use Panel

11:08

CIVM Qualification Framework Workshop Session 1: Global Perspective and Discussion of Use Part 4

10:36

CIVM Qualification Framework Workshop Session 1: Global Perspective and Discussion of Use Part 3

13:11

CIVM Qualification Framework Workshop Session 1: Global Perspective and Discussion of Use Part 2

14:01

CIVM Qualification Framework Workshop Session 1: Global Perspective and Discussion of Use Part 1

09:27

Day 1 CIVM Qualification Framework Public Workshop: Session 1 C-Path 2023 Workshop Recap

27:16

Day 1 CIVM Qualification Framework Public Workshop Keynote Address: Sonja Beken

24:16

Day 1 CIVM Qualification Framework Public Workshop: Keynote Address York Tomita

08:22

Complex In Vitro Model (CIVM) Qualification Framework Public Workshop Day 1: Opening Remarks

01:11:56

CGIC2024 Day 2 Opening Remarks & Session 1: From Data to Knowledge.

01:01:20

CGIC2024 Day 2: A Potential New Framework to Advancing Drug Development

01:05:17

CGIC2024 Day 2 Session: Living Experiences in Action — Advocacy Update Across Rare Diseases

59:11

CGIC2024 Day 2 Session: Identifying and Quantifying Sources of Variability

53:10

GGIC2024 Welcome and Session 1: Impact of Global Public-Private Collaborations on Drug Development.

01:00:55

CGIC2024 Day 1 Session: Characterizing Conditions with a Drug Development Mindset

16:13

CGIC2024 Day 1 Fireside Chat: Maximizing the Impact of CDER-led Efforts

58:34

CGIC2024 Day 1: Navigating the PFDD Roadmap: Update on the RD-COA Resource

01:02:48

CGIC2024 Day 1: Transformative Tools to Capture Early Stages of Disease: DHTs

01:10:05

CGIC2024 Day 3: Opening Remarks & Session 1: Evidentiary Considerations for Drug Development Tools

01:01:54

CGIC2024 Day 1: Transformative Tools to Capture Early Stages of Disease

01:09:27

CGIC2024 Day 3: Advancing Tangible Real-World Evidence Case Studies

55:46

CGIC2024 Day 3: Patient-Focused Drug Development in the Age of Cell and Gene-Based Therapies

01:04:57

CGIC2024 Day 1: AI Algorithm Literacy

01:03:29

CGIC2024 Day 3: Transforming Translational Sciences: From Biomarkers to New Approach Methodologies

01:03:35

CGIC2024 Day 3: Leveraging Learnings for the Future of Drug Development

01:01

Complex In Vitro Model (CIVM) Qualification Framework Public Workshop

02:47

Steve Gleason Welcomes Guests to Day 2 of #CGIC24

02:47

Steve Gleason's Welcome to CGIC Guests on Day 2 of #CGIC24

01:19

C-Path: 20 Years of Impact

05:28

CGIC 2024: Redefining Neurodegenerative Diseases with Parkinson's Disease Researcher John Seibyl

54:32

COA Second Public Discussion

09:20

CPP CODR Database — Data Standards: Why are they needed

04:25

C-Path's Vice President of Global Affairs Cecile Ollivier Discusses C-Path's Global Impact

04:18

C-Path's Impact on Rare Disease Drug Development - Klaus Romero, CEO

04:35

C-Path's RDCA-DAP Executive Director Alexandre Betourne talks about data sharing with RDCA-DAP

04:11

C-Path's Polycystic Kidney Disease Outcomes Consortium Executive Director Sorin Fedeles

03:25

VP of C-Path Rare and Orphan Disease Programs Collin Hovinga Talks Rare Disease Drug Development

04:37

Critical Path for Duchenne Muscular Dystrophy Executive Director Ramona Belfiore-Oshan

01:39

The importance of data sharing in rare disease drug development - Ramona Walls, C-Path

01:47

ALS TDI's Nadia Sethi Talks About ALS Data Sharing at C-Path's Rare & Orphan Disease Conference

02:38

C-Path Director of Outreach Thomas Hart Discusses C-Path's Work in Rare & Orphan Disease

02:10

ALS Strategy Consultant Andrea Pauls Backman Discusses C-Path's Work

02:00

ALS Advocate Cathy Collet Discusses C-Path's Work in Rare Disease